Adjunctive use of reboxetine in schizophrenia
Authors:
- Thomas J. RaedlerTRThomas J. Raedler
- Holger JahnHJHolger Jahn
- Josef ArltJAJosef Arlt
- Falk KieferFKFalk Kiefer
- Mildred SchickMSMildred Schick
- Dieter NaberDNDieter Naber
- Klaus WiedemannKWKlaus Wiedemann
- 1 September 2004
- journal article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 19 (6) , 366-369
Abstract
Background: Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms.Methods: Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4–8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 ± 17 d).Results: All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (allP< 0.01).Conclusion: The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.Keywords
This publication has 23 references indexed in Scilit:
- Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2003
- Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic AgentsAmerican Journal of Psychiatry, 2000
- At Issue: Hierarchical Diagnosis in Chronic Schizophrenia: A Clinical Study of Co-occurring SyndromesSchizophrenia Bulletin, 2000
- Reboxetine: a double-blind comparison with fluoxetine in major depressive disorderInternational Clinical Psychopharmacology, 1999
- Citalopram as an adjuvant in schizophreniaInternational Clinical Psychopharmacology, 1997
- An open trial of adjunctive sertraline in the treatment of chronic schizophreniaActa Psychiatrica Scandinavica, 1996
- What are the functional consequences of neurocognitive deficits in schizophrenia?American Journal of Psychiatry, 1996
- Pharmacotherapy of Impaired Affect in Recovering Schizophrenic PatientsArchives of General Psychiatry, 1995
- A depression rating scale for schizophrenicsSchizophrenia Research, 1990
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960